Market Trends of Japan Diabetes Drugs Industry
The oral anti-diabetic drugs segment holds the highest market share in the Japan Diabetes Drugs Market in the current year
Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action.
Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
The prevalence of diabetes is growing among all ages in Japan, which can be attributed to the growing obese population, unhealthy diets, and sedentary lifestyles. Diabetes mellitus is of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments.
The Japanese healthcare system includes a few disease management programs conducted by the Japan Association for Diabetes Education and Care. Japan is one of the regional leaders in Asia-Pacific in terms of diabetic public health policies. The country promotes public awareness and embraces preventive policies focusing on lifestyle and dietary adjustments, which can lessen the likelihood of adult-onset diabetes.
Owing to the above factors, the market will likely continue to grow.
Sodium-glucose cotransport -2 (SGLT-2) inhibitor segment is expected to register the highest CAGR in the Japan Diabetes Drugs Market over the forecast period
SGLT-2 inhibitors, also called gliflozins, are a medicine class used to lower high blood glucose levels in people with type 2 diabetes. SGLT-2 inhibitors act independently of beta-cell function in the pancreas.
SGLT-2 drugs significantly manage cardiovascular risk factors, including blood pressure, cardiac function, and anti-inflammatory activity.SGLT-2 inhibitors are effective at lowering hemoglobin A1c levels and improving weight loss. They include a low risk of hypoglycemia and are usually well tolerated.
The high prevalence of type 2 diabetes is associated with a significant economic burden. The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications.
Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and people with diabetes can visit doctors freely in Japan. Such advantages helped the increased adoption of these products in the Japanese market.
